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Abstract
Background: High-grade prostatic intraepithelial neoplasia (HGPIN) is a precursor lesion to
prostate cancer (CaP). UK-based studies examining the occurrence of isolated HGPIN and
subsequent risk of CaP are lacking. Our aim was to assess the occurrence of HGPIN in a regional
UK population and to determine whether in a retrievable cohort of such patients that had repeat
extended core biopsies, there was an elevated risk of CaP.
Methods: A retrospective analysis of the pathology database was conducted at our institution
(Lancashire Teaching Hospitals NHS Foundation Trust) for prostate biopsies recorded between
January 2001 and December 2005 (all extended core biopsies). Those patients with isolated
HGPIN on 1st set of biopsies were identified and, their clinical characteristics and pathological
findings from subsequent biopsies (if any) were determined. The risk of CaP on subsequent biopsies
based on presenting baseline PSA was stratified.
Results: Of 2,192 biopsied patients, there were 88 cases of isolated HGPIN of which 67 patients
underwent one or more repeat biopsies. In this repeat-biopsy group, 28 CaP diagnoses were made.
Age at first biopsy (P < 0.001), higher mean baseline prostate-specific antigen (PSA) (P < 0.005) and
higher mean change in PSA (P < 0.05) were predictive of CaP detection on repeat biopsies. PSA
ranges and their associated predictive values for cancer were: 0 to 5 ng/ml – 11%; 5 to 10 ng/ml –
34%; 10 to 20 ng/ml – 50%; and > 20 ng/ml – 87.5%.
Conclusion: Based on our results, we recommend delaying the 1st repeat biopsy at low PSA range
but to have a shorter interval to repeat biopsies at intermediate and higher PSA ranges.
Background
High-grade prostatic intraepithelial neoplasia (HGPIN) is
a precursor lesion to prostate cancer (CaP). Like CaP, the
incidence of HGPIN increases with age and has a higher
prevalence in African-American men [1]. HGPIN is more
frequently found in prostates with cancer than those with-
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out [2] and, tends to be multifocal and located in the
peripheral zone [3]. Similar genetic and molecular
changes in HGPIN and CaP have been described [4]. Stud-
ies prior to the mid-1990s that examined cancer risk on
subsequent prostate biopsies after diagnosis of isolated
HGPIN showed a 27% to 100% elevated risk. Since the
widespread adoption of extended core biopsy techniques,
it has been suggested that there is a lower risk of CaP
detection on repeat biopsies [5,6]. In fact, some studies
now cast doubt on whether isolated HGPIN is associated
with a high risk of CaP on repeat biopsies [5,7,8]. Reduced
rates of CaP detection on repeat biopsies have been attrib-
uted to widespread prostate-specific antigen (PSA) screen-
ing resulting in early, small-volume cancer at diagnosis,
and adoption of extended core biopsy techniques that
sample more extensively the lateral regions of the prostate
[5].
Almost all the recent studies that examine the risk of CaP
detection following diagnosis of isolated HGPIN are
based on US populations where PSA screening is wide-
spread [6,9]. The corresponding UK-based experience
examining the occurrence of isolated HGPIN and subse-
quent risk of CaP detection on repeat biopsies remains to
be determined. The aim of this retrospective study was to
exploit the pathology database in a UK hospital in order
to evaluate the occurrence of isolated HGPIN in a specific
regional population and, to determine whether in a
retrievable cohort of such patients who had repeat biop-
sies, there was a subsequent elevated risk of CaP.
Methods
With appropriate approval from the institutional audit
department, a retrospective analysis of the pathology
database was conducted at our institution (Lancashire
Teaching Hospitals NHS Foundation Trust) for prostate
biopsies recorded between January 2001 and December
2005. Those patients during this period with isolated
HGPIN on 1st set of prostate biopsies were identified. In
these men with isolated HGPIN, the clinical characteris-
tics and pathological findings from subsequent biopsies
(if any) were also determined. Patient characteristics
between those that went on to develop CaP and those that
were found to have benign histology on subsequent biop-
sies were compared (unpaired Student t-test). All P-values
given are two-tailed.
A further sub-group analysis looking at the subsequent
risk of CaP based on the level of presenting PSA was per-
formed to determine whether the risk was purely due to
HGPIN or possibly due to concurrent CaP that was not
biopsied at the time of 1st biopsy. A Kaplan-Meier type
estimator plot was generated using GraphPad Prism soft-
ware (Version 4) based on this PSA sub-group data; diag-
nosis of CaP (on repeat biopsies) was assessed as the
endpoint of interest.
Results
During this period, extended core needle prostate biopsies
were performed in a cohort of 2,087 men, of which 88
men (4.2%) had isolated HGPIN and 972 (46.6%) were
diagnosed with CaP. In the 88 patients with isolated
HGPIN on 1st set of prostate biopsies, the median age was
68 y (range 53 y to 84 y). Their mean PSA before the 1st set
of prostate biopsies was 11.45 ng/ml (median 8.5; range
0.6–68.2) and they had a median of 12 core prostate biop-
sies (range 8 to 14).
Of the 88 patients with isolated HGPIN, 67 patients
underwent one or more repeat biopsies at our institution.
In those who had repeat biopsies, CaP was subsequently
diagnosed in 28 patients (41.8% of 67 patients). Twenty-
four (32.8%) were found to have CaP on 1st set of repeat
prostate biopsies at a median interval of 13.5 months. The
number cores taken on the initial prostate biopsy and the
number of cores with HGPIN on the 1st biopsy were not
associated with subsequent CaP detection (data not
shown). The isolated HGPIN was originally reported as
unifocal in 20 patients (71%) who were subsequently
diagnosed with CaP on repeat biopsies.
Patient characteristics between those that went on to
develop CaP and those that were found to have benign
histology on subsequent repeat biopsies were compared
(Table 1). Those who were subsequently diagnosed with
CaP were significantly older (y; P  < 0.001) and had a
higher mean PSA (P < 0.005) at 1st set of prostate biopsies.
Patients that remained CaP-free had on average 1.4 repeat
biopsies (range 1 to 3) at a median interval of 13.6
months (range 1 to 57 months) while, those that devel-
oped CaP had on average 1.25 (range 1 to 3) biopsies at a
median interval of 14.5 months (range 1 to 42 months).
There was a significantly higher change in mean PSA (P <
0.05) in those that were found to have CaP on repeat
biopsies. Gleason 7 or higher tumours were detected in
35.7% of these patients who were subsequently diag-
nosed with CaP (Table 1).
We performed a sub-group analysis at different PSA ranges
(Table 2; Figure 1). At PSA range ≤ 5 ng/ml there were 15
men with HGPIN; 9 of these underwent repeat biopsies at
a mean interval of 6 m (range 1 to 14 months). Two had
one further set of biopsies and in 1, CaP was diagnosed.
There was virtually no change in the PSA (mean change of
0.3 ng/ml) in these men who had repeat biopsies. For
those with presenting PSA between 5 and 10 ng/ml, CaP
was diagnosed in 11 men of the 32 who had repeat biop-
sies. The repeat biopsies were performed at a mean inter-
val of 16.7 months (range 1 to 36 months) while theBMC Urology 2009, 9:3 http://www.biomedcentral.com/1471-2490/9/3
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Table 1: Comparison between patients with benign and malignant histology on repeat prostate biopsies
Patient characteristics Remained benign (n = 39) Developed CaP (n = 28) P-value
HGPIN at 1st set of biopsies
Mean age (y) 63.5 69.8 < 0.001
Mean PSA (ng/ml) 8.4 17.5 < 0.005
Mean number of biopsy cores 11 10.54 0.3
Unifocal HGPIN 27 20
At repeat biopsies
Mean number of repeat biopsies (range) 1.4 (1–3) 1.3 (1–3)
Mean interval (months) to 1st repeat biopsies 7.38 15.11 < 0.0005
Mean change in PSA (ng/ml) 0.5 4.8 < 0.05
Gleason score
< 7 na 18
7n a 7
> 7 na 3
Prostate cancer-free interval from the time of 1st biopsy, according to PSA levels at presentation Figure 1
Prostate cancer-free interval from the time of 1st biopsy, according to PSA levels at presentation.BMC Urology 2009, 9:3 http://www.biomedcentral.com/1471-2490/9/3
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mean change in PSA was only 1.3 ng/ml in this cohort of
men. The cancer detection rate was markedly higher in
men with PSA ≥ 10 ng/ml. For PSA range > 10 ≤ 20 ng/ml,
it was 50%; in those with presenting PSA > 20 ng/ml, it
was 87.5%.
Discussion
Recent reviews on HGPIN have found that it has a median
incidence of 5.2% (mean of 7.7%) on needle biopsies.
From data derived from recent studies, in men who are
identified to have isolated HGPIN on a 1st set of biopsies,
there is a median elevated risk of 24% (mean 31.5%) of
subsequent CaP on repeat needle biopsies [5,6]. Two-
thirds of the 22 contemporary studies (since 2000)
reviewed reported the median elevated risk of subsequent
CaP to be below 24% [6]. In fact, with the widespread
implementation of extended core (≥ 8) biopsies that
result in a more rigorous examination of the lateral
regions of the prostate, it has been suggested that identifi-
cation of isolated HGPIN may no longer be associated
with higher CaP risk on repeat biopsies. Thus, the CaP-
detection rate post-HGPIN on 1st set of biopsies may not
be markedly dissimilar to that on repeat biopsies follow-
ing an original benign diagnosis [5,10].
There appears to be no common consensus regarding the
optimal biopsy technique and schedule for repeat biop-
sies after isolated HGPIN diagnosis on 1st set of biopsies.
Three to six monthly repeat biopsies for 2 y followed by
yearly biopsies for life has been recommended [11]. Some
studies have shown a low detection rate when biopsies are
repeated within 12 months after isolated HGPIN on
extended core 1st biopsies [6,10]. Lefkowitz et al. (2002)
looked at follow-up biopsies at 3 years that showed a CaP-
detection rate of 25.8%; based on these results they rec-
ommended delaying the repeat biopsies for 3 years [12].
There has also been a suggestion for site-directed repeat
biopsies after isolated HGPIN on extended core 1st biop-
sies [13]. Men with multifocal isolated HGPIN have been
implicated to be at greater risk of developing CaP in some
studies [13,14].
Our current UK-based study showed a 41.8% risk of sub-
sequent diagnosis CaP in men with an original diagnosis
of isolated HGPIN on 1st set of biopsies, which is higher
than most contemporary studies examining extended core
repeat biopsy techniques [6]. However, this rate is compa-
rable to earlier U.S.-based study from the mid-1990s
when there was lower level of PSA screening and fewer
cores were sampled on prostate biopsies [15].
The sub-analysis based on PSA ranges showed that the ele-
vated risk of CaP detection was only observed at higher
PSA ranges. This would suggest two important findings.
Firstly, as purely isolated HGPIN should not raise the PSA
so patients with low age specific PSA (especially in the PSA
range ≤ 5 ng/ml) may be appropriate candidates for repeat
biopsies at longer intervals as suggested by Lefkowitz et al.
(2002) [12]. Secondly, the negative 1st biopsy in the pres-
ence of a high PSA may be a reflection of a missed concur-
rent focus of CaP and in these patients a repeat biopsy
strategy at a shorter interval may be more appropriate. A
similar strategy in the intermediate PSA range (between 5
to 10 ng/ml) may be justified as the risk of subsequent
diagnosis of CaP on repeat biopsies seems to be still high
(Table 2; Figure 1). We present part of the data in the Kap-
lan-Meier type plot (Figure 1); it is important to realise
that as the Kaplan-Meier method uses a finite number of
observations to provide information for estimation pur-
poses, one should use caution in deducing important con-
clusions based solely from the curve.
There are a number of limitations to the current study.
Either due to patient choice or due to their co-morbidities
or for some unknown reasons, 21 patients with diagnosis
of HGPIN on first set of biopsies did not undergo repeat
biopsies at our institution. Though these patients were rel-
atively older with a mean age of 73 y, no significant differ-
ence in the mean PSA level or mean number of biopsy
cores at 1st set of biopsies was observed when compared to
those that had repeat biopsies (data not shown). In 18 of
these 21 patients the clinic follow-up data was available
and none of these men have shown rapid rise in PSA or
Table 2: Detection rates of prostate cancer in men with HGPIN based on the baseline PSA level at first biopsy
PSA range 
(ng/ml)
Mean PSA in ng/
ml (range)
No. men with 
HGPIN
Mean age [y 
(range)]
No. undergoing 
repeat biopsies
CaP diagnosis Percentage with 
CaP diagnosis†
≤ 53 . 3
(1.5 to 5)
15 61.7
(52 to 74)
91 1 1
> 5 ≤ 10 7.1
(5.2 to 9.5)
37 65.4
(52 to 81)
32 11 34
> 10 ≤ 20 13.5
(10.1 to 19.7)
28 70.1
(61 to 86)
18 9 50
> 20 34.5
(21.3 to 68.2)
87 3 . 7
(62 to 84)
87 8 7 . 5
† Calculated as a percentage of those that underwent repeat biopsies and were subsequently detected with CaPPublish with BioMed Central    and   every 
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clinical progression to CaP. Also, there does not appear to
have been a uniform protocol for repeat biopsies. Further-
more, this is a retrospective study looking at a regional
population and, thus may not be representative of the sit-
uation in the UK as a whole. Prospective or retrospective
studies looking at multiple regions may be needed to
examine this more fully.
Conclusion
In this UK-based study a presentation of isolated HGPIN
at 1st set of extended core needle prostate biopsies was
associated with a high risk (41.8%) of a subsequent diag-
nosis of CaP on repeat biopsies. Patient age, higher PSA
level at isolated HGPIN diagnosis and higher mean
changes in serum PSA levels were predictive of CaP detec-
tion on repeat biopsies. Based on the results of our study,
we recommend delaying the first repeat biopsy at low PSA
range and repeat biopsies at shorter interval at intermedi-
ate and higher PSA ranges.
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